drugset / Trial / NCT02964338
A Study Comparing the Efficacy and Safety of Fremanezumab (TEV-48125) for the Prevention of Chronic Cluster Headache (CCH)
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of the current study is to evaluate the efficacy and safety of Fremanezumab (TEV-48125), in the prevention of CCH in adult participants.
Timeline
- Start
- 2017-01-17
- Primary completion
- 2018-07-18
- Completion
- 2018-07-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fremanezumab | Monoclonal antibody | 225 mg | Intravenous |